Press Release

SOLVAY

EMBARGO: Brussels, October 28, 2010 at 7:30 AM
REGULATED INFORMATION

Operating result from the Chemicals and Plastics activities for the third quarter of 2010 (EUR 149 million) significantly higher (+60% at constant scope[1]) compared to the third quarter of 2009

- ✓ **Sales (EUR 5,461 million):** at constant scope[1], up by 22% compared to the end of September 2009, in the context of a more sustained global activity; up by 21% in the third quarter
- ✓ **Operating result[2] (EUR 478 million[3])**
  - ➢ Overall, the operating result benefited from efforts to control costs
  - ➢ **Chemicals (EUR 230 million)**: up by 18% compared to the end of September 2009 thanks to improvement in sales volumes across all activities
  - ➢ **Plastics (EUR 261 million)**: clearly improved compared to the first nine months of 2009 (EUR 56 million) especially thanks to significant increase in sales volumes in Specialty Polymers
- ✓ **Net income of Group (EUR 1,807 million)** up compared to the end of September 2009 thanks to the capital gains realized on the sale of the pharmaceuticals activities and on the sale of Inergy Automotive Systems; in the third quarter, impairment on industrial assets, primarily in soda ash in Europe, with an impact on net income of the Group of EUR -197 million.
- ✓ **Interim dividend** of 0.90 EUR net per share (1.20 EUR gross per share)

Group **sales** at the end of September 2010 amounted to EUR 5,461 million. At constant scope[1], they were up by 22%. Sales from the Chemicals Sector (EUR 2,226 million) improved by 8% compared to the end of September 2009. Sales volumes, significantly up (+14%), compensated for the lower sales prices (-10%). Sales from the Plastics Sector (EUR 2,923 million) were clearly improved (+36% at constant scope[1] compared to nine months of 2009), especially thanks to significant increase in sales volumes in Specialty Polymers, up by 42% compared to last year.

Recurring Group operating result (**REBIT**[2-4]) from the first nine months of 2010 amounted to EUR 478 million. REBIT from continuing operations was clearly improved compared to last year, both on a cumulative basis (EUR 447 million at the end of September 2010, that is +98% at constant scope[1]) and on a quarterly basis (EUR 149 million in the third quarter 2010, that is +60% at constant scope[1]).

The Group's **operating margin** (REBIT on sales), excluding the pharmaceuticals activities, was 8.7% at the end of September 2010 compared to 5.2% at the end of September 2009; it reached 8.8% in the third quarter of 2010.

The **net income of the Group** (EUR 1,807 million) was up compared to the end of September 2009 thanks to the capital gain realized on the sale of the pharmaceuticals activities (EUR 1.7 billion net of taxes). Net income of the third quarter of 2010 (EUR 18 million) was impacted, on the one hand, positively by the capital gain realized on the sale of Inergy Automotive Systems (EUR 130 million after taxes) and, on the other hand, negatively by impairments – non cash – on industrial assets (impact after taxes of EUR -197 million). These impairments involve almost exclusively the soda ash activity in Europe confronted with the ongoing weakness in some of its markets, especially flat glass used by construction. Industrial measures have been taken: capital expenditures have been drastically reduced and will remain at a low level as long as end markets remain sluggish. Our commercial policy will be revisited and if insufficient, new industrial measure will be considered.

REBITDA[2-5] of the Group amounted to EUR 798 million. Excluding pharmaceuticals activities, it was up by 50% compared to the end of September 2009.

On October 27, 2010, the Board of Directors decided on payment, for the current year, of an **interim dividend** of 0.90 EUR net per share (1.20 EUR gross per share), which corresponds, as usual, to 40% (rounded) of the total dividend of last year.

Following the sale of the pharmaceuticals activities on February 15, 2010 and of its 50% stake in Inergy Automotive Systems on September 8, 2010 and in anticipation of reinvestment of these funds in industrial activities, the Solvay Group is in a **net cash surplus** situation (EUR 2,881 million, or 42% of equity).

Chemicals Sector sales at the end of September 2010 (EUR 2,226 million) improved by 8% compared to last year. Sales volumes, up significantly (+14%), compensated for the lower sales prices (-10%) - especially in soda ash. In the third quarter of 2010, sales (EUR 782 million) improved by 19%. At the end of September 2010, the operating result (EUR 230 million) was up by 18% compared to last year (EUR 195 million); in the third quarter, it amounted to EUR 83 million compared to EUR 62 million from last year. This increase involves all of the Chemicals activities with the exception of soda ash. This is explained, on the one hand, by the significant increase in sales volumes and, on the other hand, by energy expenses that were under control. These expenses, however, are expected to increase in the fourth quarter.

1 The primary variations in perimeter between nine months of 2009 and nine months of 2010 are shown on page 15 of the press release.
2 The cost of discounting provisions (EUR 49 million as of September 30, 2009 and EUR 40 million on September 30, 2010) was transferred to financing rather than operating charges in line with IAS19, considering the financial nature of this item.
3 Includes the operating result of the 5 segments of the Group (Chemicals, Plastics, New Business Development, Corporate and Business Support and Pharmaceuticals (up to February 15, 2010)).
4 REBIT : measure of operating performance (this is not an IFRS concept as such)
5 REBITDA : REBIT, before recurring depreciation and amorization

Plastics Sector sales were clearly up compared to last year; at constant scope[6], they improved by 36% on a cumulative basis (EUR 2,923 million at the end of September 2010) and by 23% on a quarterly basis (EUR 918 million in the third quarter of 2010). This can be explained by the sharp increase in sales volumes in Specialty Polymers. Although all regions of the world were involved, this improvement was particularly notable in Asia. In Vinyls, improvement in sales was confirmed in the third quarter. SolVin was able to benefit from the slight recovery in demand in a context of supply that was temporarily more limited. Operating result from the Plastics Sector (EUR 261 million at the end of September 2010 and EUR 88 million in the third quarter of 2010) was clearly improved compared to last year (EUR 56 million at the end of September 2009 and EUR 42 million in the third quarter of 2009). This improvement was observed in both Vinyls and Specialty Polymers, although it was the latter that showed the highest growth in results.

The purchase by Plastic Omnium of Solvay's stake in Inergy Automotive Systems closed on September 8, 2010. The capital gain realized by Solvay on this sale amounted to EUR 130 million after taxes.

The Group's operating result benefits from the improvements in competitiveness and in sales volumes.
Solvay expects a higher REBIT in Chemicals compared to last year. Taking into account the significantly stronger demand for specialty polymers experienced in the first nine months, Solvay will realize a sharply improved REBIT in Plastics compared to the low level of last year.
This year, the priority continues to go to the optimal reinvestment after the disposal of the pharmaceuticals activities.

SOLVAY Group – Summary Financial Information

Million EUR (except for per-share figures in EUR)	9 months 2009	9 months 2010	9 months 2010/ 9 months 2009	3rd quarter 2009	3rd quarter 2010	3rd quarter 2010/ 3rd quarter 2009
Sales	**6,286**	**5,461**	**-13%**	**2,235**	**1,700**	**-24%**
REBIT	**641**	**478**	**-25%**	**302**	**149**	**-51%**
REBIT – continuing operations	**222**	**447**	**102%**	**95**	**149**	**57%**
REBIT – discontinued operations	**419**	**31**	ns	**206**	**0**	**-100%**
REBIT/Sales	*10.2%*	*8.8%*	ns	*13.5%*	*8.8%*	ns
Non-recurring items	-64	-239	ns	-30	-123	ns
EBIT[7]	**577**	**239**	**-59%**	**272**	**26**	**-90%**
Charges on net indebtedness	-167	-139	-16%	-63	-48	-23%
Income on investments	-3	-1	-60%	0	-2	ns
Capital gain Pharma	0	1,703	ns	0	8	ns
Earnings before taxes	**407**	**1,802**	**ns**	**209**	**-15**	**ns**
Income taxes	-53	4	ns	-36	33	ns
Net income of the Group	**354**	**1,807**	**ns**	**173**	**18**	**-90%**
Net income (Solvay share)	328	1,779	ns	160	11	ns
Total depreciation	395	613	55%	133	355	167%
REBITDA	1,011	798	-21%	426	249	-42%
Cash flow	749	2,420	ns	306	373	22%
Results per share[8]	**3.99**	**21.85**	**ns**	**1.95**	**0.13**	ns
Net debt to equity ratio	36%	-42%				

Notes on Solvay Group summary financial information

Non-recurring items amounted to EUR -239 million at the end of September 2010. They include impairments on industrial assets posted in the third quarter of EUR -261 million (before taxes), primarily in soda ash in Europe due to the persistent weakness of some markets in this line of business, the capital gain of EUR 139 million (before taxes) on the sale of Inergy Automotive Systems, an asset write-off of EUR 20 million related to the closed hydrogen peroxide unit at Bitterfeld, other restructuring charges on fluorinated products in Germany and in Italy for EUR 20 million and an environmental provision of EUR 19 million for remediation and containment works in Spinetta (Italy).

Charges on net indebtedness amounted to EUR –139 million at the end of September 2010 compared to EUR –167 million at the end of September 2009. Charges on borrowing amounted to EUR -108 million. Gross financial debt is at 82% covered at an average fixed rate of 5.1% with a duration of 5.4 years; the first significant maturity for debt reimbursement will not occur until 2014. Interest on cash deposits and investments amounted to EUR 16 million. It should be recalled that the proceeds from the sale of the pharmaceuticals activities have been invested in short

6 The primary variations in the perimeter between nine months 2009 and nine months 2010 are shown on the page 15 of this press release.
7 EBIT : results before financial charges and taxes
8 Calculated on the basis of the weighted average of the number of shares in the period, after deduction of treasury shares and own shares purchased to cover the stock option program, or a total of 82,136,569 shares for nine months 2009 and 81,431,355 shares for nine months 2010

duration government bonds and highest rated treasury instruments since February 15, 2010. Annual cash yield at the end of September 2010 was 0.4%.

The **capital gain** realized on the **sale of the pharmaceuticals activities** amounted to EUR 1.7 billion net of taxes.

Income taxes at the end of September 2010 amounted to EUR +4 million compared to EUR –53 million last year. The tax amount posted in the third quarter of 2010 (EUR +33 million) is explained by a deferred tax asset of EUR 64 million on impairments – non cash – of industrial assets (non-recurring charge of EUR 261 million before taxes). Aside from this exceptional item and not considering the capital gains realized on the sale of the pharmaceuticals activities and on the sale of Inergy Automotive Systems, the effective tax rate would be 24%.

The **net income of the Group** (EUR 1,807 million) was improved compared to the end of September 2009 thanks to the capital gain realized on the sale of the pharmaceuticals activities (EUR 1.7 billion net of taxes). The **"non-controlling interests"** amounted to EUR 27 million. The **net result per share** amounted to 21.85 EUR (compared to 3.99 EUR at the end of September 2009).

Our conservative policy on capital expenditures in the wake of a fragile recovery and weak end markets for soda ash in Europe and USA has allowed us to generate **free cash flow from continuing operations** - thus excluding any return on the reinvestment of the proceeds from the sale of the pharmaceutical sector - of EUR 160 million at the end of September 2010. It includes an amount of EUR -206 million related to the substitution of a previously issued guarantee by a prepayment in the first quarter of 2010, of fines imposed in 2006 by the European Commission concerning peroxygen antitrust cases (still in appeal), as well as the proceeds from the sale of our 50% stake in Inergy Automotive Systems (EUR 268 million). It should be noted that the Group continues its efforts regarding the rigorous management of **working capital.** Industrial working capital of continuing operations amounted to EUR 1,179 million at the end of September 2010, slightly up (EUR 77 million) compared to the end of September 2009 in a clearly improved sales context (+21%).

RESULTS BY SEGMENT[9]

Million EUR	9 months 2009	9 months 2010	9 months 2010 / 9 months 2009	3rd quarter 2009	3rd quarter 2010	3rd quarter 2010/ 3rd quarter 2009
GROUP SALES[10]	**6,286**	**5,461**	**-13%**	**2,235**	**1,700**	**-24%**
Chemicals	2,064	2,226	8%	658	782	19%
Plastics	2,180	2,923	34%	827	918	11%
Sales – continuing operations	**4,243**	**5,149**	**21%**	**1,484**	**1,700**	**15%**
Pharmaceuticals – Discontinued Operations	2,043	312	ns	751	0	ns
REBIT GROUP	**641**	**478**	**-25%**	**302**	**149**	**-51%**
Chemicals	195	230	18%	62	83	33%
Plastics	56	261	ns	42	88	112%
Corporate and Business Support	-12	-24	100%	-3	-15	ns
New Business Development	-17	-19	13%	-6	-7	16%
REBIT – continuing operations	**222**	**447**	**+102%**	**95**	**149**	**57%**
Pharmaceuticals – Discontinued Operations	419	31	ns	206	0	ns
REBITDA GROUP	**1,011**	**798**	**-21%**	**426**	**249**	**-42%**
Chemicals	320	373	16%	105	128	22%
Plastics	213	432	103%	94	141	50%
Corporate and Business Support	-6	-19	ns	-1	-13	ns
New Business Development	-17	-19	15%	-6	-7	18%
REBITDA – continuing operations	**510**	**767**	**50%**	**192**	**249**	**29%**
Pharmaceuticals – Discontinued Operations	501	31	ns	233	0	ns

It should be noted that the "New Business Development" (NBD) segment in 2009 showed a REBIT of EUR -25 million, constituted for the most part of research costs. Included in 2009 in the "Corporate and Business Support" segment, it has been part of specific reporting since January 1, 2010.
The R&D budget for NBD in 2010 amounted to about EUR 30 million.

9 Results by segment include results from the five segments of the Group (until February 15, 2010 for Pharma).
10 These are sales after elimination of inter-company sales.

IFRS FINANCIAL STATEMENTS

CONSOLIDATED INCOME STATEMENT AT THE END OF SEPTEMBER

	9 months 2009			9 months 2010		
Million EUR (except for per-share figures in EUR)	**Continuing Operations**	**Discontinued operations**	**Total**	**Continuing Operations**	**Discontinued operations**	**Total**
Sales	**4,243**	**2,043**	**6,286**	**5,149**	**312**	**5,461**
Cost of goods sold	-3,518	-575	-4,093	-4,169	-90	-4,260
Gross margin	**725**	**1,468**	**2,193**	**979**	**222**	**1,202**
Commercial and administrative costs	-394	-728	-1.121	-412	-134	-546
Research and development costs	-105	-316	-421	-104	-45	-149
Other operating gains and losses	-34	-10	-43	-45	-9	-54
Other financial gains and losses	29	4	33	28	-2	26
REBIT	**222**	**419**	**641**	**447**	**31**	**478**
Non-recurring items	-41	-23	-64	-239	0	-239
EBIT	**180**	**396**	**577**	**208**	**31**	**239**
Cost of borrowings	-12	-92	-104	-104	-4	-108
Interest on lendings and short-term deposits	0	7	7	15	1	16
Other gains and losses on net indebtedness	-17	-4	-20	-8	0	-8
Cost of discounting provisions[11]	-41	-9	-49	-40	0	-40
Income from investments	-3	0	-3	-1	0	0
Capital gain Pharma	0	0	0	0	1.703	1.703
Earnings before taxes	**108**	**299**	**407**	**71**	**1.732**	**1.802**
Income taxes	-35	-18	-53	8	-4	4
Net income of Group	**74**	**281**	**354**	**79**	**1.727**	**1.807**
Non-controlling interests	-25	-1	-26	-27	0	-27
Net income (Solvay share)	**49**	**279**	**328**	**52**	**1.727**	**1.779**
Earnings per share (in EUR)	0.60	3.40	3.99	0.64	21.21	21.85
Diluted earnings per share (*) (in EUR)	0.60	3.40	3.99	0.64	21.17	21.81

(*) Calculated on the number of shares diluted by awarded stock options

TOTAL COMPREHENSIVE INCOME OF THE GROUP AT THE END OF SEPTEMBER

	9 months 2009			9 months 2010		
Million EUR	**Continuing operations**	**Discontinued operations**	**Total**	**Continuing operations**	**Discontinued operations**	**Total**
Net income of Group	**74**	**281**	**354**	**79**	**1,727**	**1,807**
Gains and losses on remeasuring available-for-sale financial assets	27	0	27	-8	4	-3
Effective portion of gains and losses on hedging instruments in a cash flow hedge	9	-11	-2	-2	1	-1
Currency translation differences	-43	3	-40	185	33	218
Income tax relating to components of other comprehensive income	0	5	5	1	0	1
Other comprehensive income	**-7**	**-3**	**-10**	**176**	**39**	**214**
Total comprehensive income of the Group	**67**	**278**	**344**	**255**	**1,766**	**2,021**
Attributed to:						
-owners of the parent	**37**	**277**	**313**	**193**	**1,766**	**1,959**
-non-controlling interests	**30**	**1**	**31**	**62**	**0**	**62**

[11] The cost of discounting provisions (EUR 49 million on September 30, 2009 and EUR 40 million on September 30, 2010) was transferred to financing rather than operating charges in line with IAS 19 considering the financial nature of this item.

CONSOLIDATED INCOME STATEMENT FOR THE THIRD QUARTER

	3rd quarter 2009			3rd quarter 2010		
Million EUR (except for per-share figures, in EUR)	**Continuing operations**	**Discontinued operations**	**Total**	**Continuing operations**	**Discontinued operations**	**Total**
Sales	**1,484**	**751**	**2,235**	**1,700**	**0**	**1,700**
Cost of goods sold	-1,237	-203	-1,439	-1,362	0	-1,362
Gross margin	**247**	**548**	**795**	**338**	**0**	**338**
Commercial and administrative costs	-130	-238	-368	-135	0	-135
Research and development costs	-36	-95	-131	-31	0	-31
Other operating gains and losses	-2	-6	-8	-28	0	-28
Other financial gains and losses	15	-2	13	5	0	5
REBIT	**95**	**206**	**302**	**149**	**0**	**149**
Non-recurring items	-26	-4	-30	-123	0	-123
EBIT	**69**	**202**	**272**	**26**	**0**	**26**
Cost of borrowings	-10	-28	-38	-37	0	-37
Interest on lendings and short-term deposits	0	2	2	6	0	6
Other gains and losses on net indebtedness	-5	-5	-10	-3	0	-3
Cost of discounting provisions[12]	-14	-2	-16	-14	0	-14
Income from investments	0	0	0	-1	0	-1
Capital gain Pharma	0	0	0	0	8	8
Earnings before taxes	**40**	**169**	**209**	**-23**	**8**	**-15**
Income taxes	-13	-23	-36	33	0	33
Net income of Group	**27**	**146**	**173**	**10**	**8**	**18**
Non-controlling interests	-12	-1	-12	-7	0	-7
Net income (Solvay share)	**15**	**145**	**160**	**3**	**8**	**11**
Earnings per share (in EUR)	0.18	1.77	1.95	0.03	0.10	0.13
Diluted earnings per share (*) (in EUR)	0.18	1.76	1.95	0.03	0.10	0.13

(*) Calculated on number of shares diluted by awarded stock options

TOTAL COMPREHENSIVE INCOME FOR THE THIRD QUARTER

	3rd quarter 2009			3rd quarter 2010		
Million EUR	**Continuing operations**	**Discontinued operations**	**Total**	**Continuing operations**	**Discontinued operations**	**Total**
Net income of Group	**27**	**146**	**173**	**10**	**8**	**18**
Gains and losses on remeasuring available-for-sale financial assets	11	-1	10	4	0	4
Effective portion of gains and losses on hedging instruments in a cash flow hedge	1	-6	-5	6	0	6
Currency translation differences	-56	-3	-59	-227	0	-227
Income tax relating to components of other comprehensive income	3	-1	2	-1	0	-1
Other comprehensive income, net of related tax effects	**-40**	**-11**	**-51**	**-218**	**0**	**-218**
Total comprehensive income of the Group	**-13**	**135**	**121**	**-208**	**8**	**-200**
Attributed to:						
-owners of parent	**-23**	**134**	**111**	**-196**	**8**	**-188**
-non-controlling interests	**10**	**0**	**10**	**-12**		**-12**

[12] The cost of discounting provisions (EUR 16 million in the third quarter of 2009 and EUR 14 million in the third quarter of 2010) was transferred to financing rather than operating charges in line with IAS 19 considering the financial nature of this item.

CONSOLIDATED BALANCE SHEET

Million EUR	December 31, 2009	September 30, 2010
Non-current assets	**5,075**	**5,027**
Intangible assets	162	122
Goodwill	76	72
Tangible assets	3,921	3,593
Available-for-sale investments	68	63
Investments and shares – Equity accounting	0	19
Other investments	209	245
Deferred tax assets	487	581
Loans and other non-current assets	152	331
Current assets	**7,471**	**9,092**
Inventories	805	838
Trade receivables	1,373	1,995
Income tax receivables	19	8
Other receivables	327	546
Other current financial assets	0	3,873
Cash and cash equivalents	1,486	1,831
Assets held for sale – Pharma	3,408	0
Assets held for sale – Other	53	0
TOTAL ASSETS	**12,546**	**14,119**
Total equity	**5,160**	**6,892**
Share capital	1,271	1,271
Reserves	3,483	5,210
Non-controlling interests	406	411
Non-current liabilities	**4,536**	**4,719**
Long-term provisions: employee benefits	895	866
Other long-term provisions	766	980
Deferred tax liabilities	196	187
Long-term financial debt	2,635	2,629
Other non-current liabilities	44	55
Current liabilities	**2,851**	**2,508**
Short-term provisions: employee benefits	7	10
Other short-term provisions	61	60
Short-term financial debt	185	194
Trade liabilities	828	1,655
Income tax payable	66	80
Other current liabilities	682	509
Liabilities associated with assets held for sale – Pharma	1,012	0
Liabilities associated with assets held for sale – Other	11	0
TOTAL EQUITY & LIABILITIES	**12,546**	**14,119**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

	Equity attributable to equity holders of the parent									
Million EUR	Share capital	Issue premiums	Retained earnings	Treasury shares	Currency translation differences	Fair value differences-Available for sale investments	Fair value differences – cash flow hedges	Total	Non-controlling interests	Total equity
Balance – 12/31/2009	**1,271**	**18**	**4,272**	**-218**	**-612**	**21**	**3**	**4,754**	**406**	**5,160**
Net profit for the period			1,779					**1,779**	27	**1,807**
Income and expenses directly allocated to equity					183	-3	-1	**180**	35	**214**
Total comprehensive income	**0**	**0**	**1,779**	**0**	**183**	**-3**	**-1**	**1,959**	**62**	**2,021**
Cost of stock options			7					**7**		**7**
Dividends			-142					**-142**	-8	**-150**
Acquisition/sale of treasury shares				-90				**-90**		**-90**
Other			-7					**-7**	-49	**-56**
Balance – 9/30/2010	**1,271**	**18**	**5,910**	**-309**	**-429**	**18**	**2**	**6,481**	**411**	**6,892**

CONSOLIDATED CASH FLOW STATEMENT

Million EUR	9 months 2009	9 months 2010
EBIT	527	238
Depreciation, amortization and impairments	395	613
Changes in working capital	-183	-191
Changes in provisions	-78	-33
Income taxes paid	-28	-66
Others	-10	-184
Cash flow from operating activities	**624**	**378**
Acquisition of investments and shares	-55	-99
Sale of investments and shares	16	4,727
Acquisition of assets	-353	-211
Sale of assets	10	18
Income from investments	0	1
Changes in loans	12	-172
Effects of changes in method of consolidation	4	-13
Cash flow from investing activities	**-366**	**4,251**
Capital increase/redemption	-17	-26
Acquisition/sale of treasury shares	-1	-90
Changes in borrowings	371	32
Changes in other current financial assets	0	-3,873
Cost of borrowings	-104	-108
Interest on lendings and short-term deposits	7	16
Other	-20	-8
Dividends paid	-253	-248
Cash flow from financing activities	**-17**	**-4,306**
Net change in cash and cash equivalents	**240**	**322**
Currency translation differences	1	23
Opening cash balance	883	1,486
Ending cash balance	**1,124**	**1,831**

Free Cash Flow[13] – continuing operations	**123**	**160**
Free Cash Flow[13] – discontinued operations	**130**	**4,481**

CASH FLOWS FROM DISCONTINUED OPERATIONS

Million EUR	9 months 2009	9 months 2010
Cash flow from operating activities	239	35
Cash flow from investing activities	-22	4,447
Cash flow from financing activities	-210	0
Net change in cash and cash equivalents	**6**	**4,482**

13 Free cash flow = cash flow from operating activities + cash flow from investing activities, excluding the effects of changes in method of consolidation

RESULTS BY SEGMENT

Million EUR	9 months 2009	9 months 2010	9 months 2010/ 9 months 2009	3rd quarter 2009	3rd quarter 2010	3rd quarter 2010/ 3rd quarter 2009
Group Sales[14]	**6,799**	**6,130**	**-10%**	**2,410**	**1,930**	**-20%**
Chemicals						
Sales[14]	2,176	2,361	9%	699	823	18%
Inter-segment sales	-113	-135		-41	-41	
External sales	2,064	2,226	8%	658	782	19%
Plastics						
Sales[14]	2,580	3,456	34%	961	1,107	15%
Inter-segment sales	-400	-533	25%	-134	-189	29%
External sales	2,180	2,923	34%	827	918	11%
Sales – Continuing operations	**4,756**	**5,818**	**22%**	**1,660**	**1,930**	**16%**
Pharmaceuticals – Discontinued Operations	2,043	312	ns	751	0	ns
EBIT GROUP	**577**	**239**	**-59%**	**272**	**26**	**-90%**
Chemicals	145	-108	ns	41	-182	ns
Plastics	49	367	ns	39	222	ns
New Business Development	-17	-19	13%	-6	-7	16%
Corporate and Business Support	3	-33[15]	ns	-5	-7	49%
EBIT – continuing activities	**180**	**208**	**15%**	**69**	**26**	**-62%**
Pharmaceuticals –Discontinued Operations	396	31[15]	ns	202	0	ns

14 These are sales before elimination of inter-company sales.
15 At the end of 2009, in the perspective of the closing of the transaction with Abbott, the Solvay Group decided to assign to the “Discontinued Operations” segment several Pharma provisions for risks which for reasons of confidentiality had been attached as of this date to the Corporate and Business Support segment.

ANNEX TO PRESS RELEASE
COMMENTS ON SOLVAY GROUP RESULTS FOR 9 MONTHS OF 2010

GROUP

Strategic refocus of Solvay Group activities

The sale of the pharmaceuticals activities to Abbott closed on February 15, 2010.

Solvay intends to reinvest the proceeds from the transaction in organic and sizeable external growth, focused on long-term value creation. The strategic focus is on investments in high value-added activities and strategic projects in chemicals and plastics, by continuing the geographic expansion into regions with growth potential, and by pursuing the development of activities and new products with low energy footprint, which we expect will reduce the cyclicality of Solvay's portfolio of activities. The reinvestment process is ongoing.

In the meanwhile, the proceeds of the sale of the pharmaceuticals activities are temporarily invested in short duration government bonds (Germany, France, The Netherlands, Belgium) for some 80% and in highest-rated treasury instruments for about 20%; and a program of investments in own treasury shares was set up for a maximum of 5.1 million shares (6% of the issued capital). On October 25, 2010, the investment in Solvay's shares since the launch of the program totaled 880,766 shares.

The Solvay Group's philosophy remains unaltered: realize sustained growth with leading positions and maintain a conservative financial structure.

In the framework of this strategic refocus, the Solvay Group did a study (the "Horizon" project) aiming to optimize the effectiveness of its organization and to prepare it for future growth. The new organizational structure, as envisaged, was communicated on September 23, 2010. Its implementation will be done in the upcoming months, pending approval by the Board of Directors and after completion of the social procedures for information and consultation of workers' representatives. Aside from improved functioning of the company, this reorganization should lead to reductions in labor cost (estimated at EUR 65 million per year) and external expenses (estimated at EUR 55 million per year). The measures planned will be gradually implemented and should produce their full effect at the end of 2012, subject to the completion of the social procedures. The social costs, estimated to reach at least one time the yearly savings, are not taken into account at this stage; the social procedures are still underway.

CHEMICALS SECTOR

Recent strategic developments

Solvay is convinced that the Chemicals field will contribute to sustainable development. Different initiatives were recently launched or finalized in this area by the Chemicals Sector.

- Advanced Biochemical Thailand, wholly-owned subsidiary of Vinythai, built in Thailand an epichlorohydrin production unit (100,000 tons/year) based on natural glycerin (EPICEROL® process). This unit will begin operation at the start of 2012. As well as using renewable raw materials, this process generates fewer byproducts and consumes less water.
- In the United States, at Green River, production of sodium bicarbonate (125,000 tons/year) from solid waste coming from production of soda ash started up in April 2010. This process enables production of SOLVAIR® Select 300, specifically designed for treatment of flue gases.
- Solvay recently launched F1EC, an electrolyte additive capable of prolonging the life cycle and increasing the safety and capacity of lithium-ion batteries. A new production unit for this product, located in South Korea, was inaugurated at the end of 2009.
- In September 2010, Solvay announced the construction, in partnership with the Chinese company Sinochem Lantian, of an installation of hydrofluoric acid production designed for the electronics industry, and in particular for production of photovoltaic panels.

It is of paramount importance for the Chemicals Sector to continuously improve the energy efficiency of its industrial processes, thereby minimizing CO_2 emissions, and to ensure a lasting, reliable and competitive supply of energy.

- The cogeneration unit built in partnership with Tönsmeier on the Bernburg site (Germany) has been operational since the start of 2010. It is supplied by secondary fuels (recovered materials). It results in significant reduction of regulated CO_2 emissions at the site and improves its competitiveness by decreasing its energy costs.
- Solvay participates in the industrial consortium Exeltium with other electro-intensive companies to ensure long-term electricity supplies at competitive prices in France. The first supplies of electricity by Exeltium to its client-shareholders began in May 2010.

- Solvay Energy has been operational since mid-2009. Its purpose is to ensure the management of energy purchases for the different businesses and to set up mechanisms for financial hedging if needed.

Technological innovation and geographic expansion in high-growth regions constitute two key strategic priorities of the Chemicals Sector. The following recent developments and projects exemplify this strategy:

- In the framework of a partnership with Dow Chemical Company, the construction of a high-yield mega-plant (330,000 tons/year) of hydrogen peroxide is under way in Thailand (startup set for the third quarter of 2011). Hydrogen peroxide from this plant will be used to produce propylene oxide. Solvay is the leader in this new, important market for hydrogen peroxide.
- Solvay is building, in partnership with the Huatai group, a hydrogen peroxide plant in China. This plant, with an annual capacity of 50,000 tons/year, will begin operations at the end of 2011.

The recent economic crisis led the Chemicals Sector to further reinforce its competitiveness. Several restructuring measures were taken during 2009, following those announced and implemented in 2008. Thus, Solvay shut down the hydrogen peroxide unit at Bitterfeld (Germany), reconfigured the Peptisyntha activity (Belgium), optimized personnel structures within Alexandria Sodium Carbonate Company (Egypt), shut down the precipitated calcium carbonate production unit at Angera and resized the Bussi site (Italy) and shut down the fluorides products production site at Catoosa (United States). Targeted restructurings undertaken in 2010 in the fluorinated products activity at Bad Wimpfen (Germany) and Porto Marghera (Italy) should also be noted.

Key figures

(Million EUR)	Sales				**REBIT change**
	2009	9 months 2009	9 months 2010	9 months 2010/ 9 months 2009 (%)	9 months 2010/ 9 months 2009
CHEMICALS[16]	**2,713**	**2,064**	**2,226**	**8%**	**18%**
Minerals cluster[17]	1,263	955	1,000	5%	↘
Electrochemistry and fluorinated products cluster	986	763	832	9%	↗
Oxygen cluster	441	329	377	15%	↗

Comments

- ***Operating result up by 18% for nine months of 2010 and by 33% in the third quarter of 2010***
- ***Clear improvement in sales volumes for all activities***
- ***Low sales prices in soda ash; expected increase in sales price for caustic soda in the fourth quarter***
- ***Increase of energy expenses anticipated***

Chemicals Sector sales at the end of September 2010 (EUR 2,226 million) improved by 8% compared to last year. Sales volumes, up significantly (+14%), compensated for the lower sales prices (-10%) - especially in soda ash. In the third quarter of 2010, sales (EUR 782 million) improved by 19%. At the end of September 2010, the operating result (EUR 230 million) was up by 18% compared to last year (EUR 195 million); in the third quarter, it amounted to EUR 83 million compared to EUR 62 million from last year. This increase involves all of the Chemicals activities with the exception of soda ash. This is explained, on the one hand, by the significant increase in sales volumes and, on the other hand, by energy expenses that were under control. These expenses, however, are expected to increase in the fourth quarter.

Minerals Cluster

- Sales for the minerals cluster at the end of September 2010 were slightly improved (+5%) compared to nine months of 2009. Since the start of the year, a slight increase in sales volumes of soda ash was observed; however, these remain significantly lower than their pre-crisis levels. While the flat glass sector (construction and automotive) remained low, improvements were seen in the container glass and detergent sectors. Geographically, European and American domestic markets remained weak while the export markets are experiencing robust growth. Average sales prices for the first nine months of 2010 were significantly lower than in 2009, on the one hand, due to persistent surplus capacity, particularly in Europe, and on the other hand, due to the greater importance of exports (at lower prices) in total sales. This had a negative impact on the operating result in the Minerals cluster, lower than in the nine months of 2009. Specialties derived from soda ash, in particular bicarbonate, continued to perform well. It should be recalled that in the second quarter of 2010, an exceptional depreciation charge of EUR 10 million was posted following the decision to terminate the sale process of the precipitated calcium carbonate activity.

Electrochemistry and fluorinated products cluster

- In **Electrochemistry**, sales improved by 6% compared to the end of September 2009. In caustic soda, improvement in sales volumes partially compensated for the negative impact of prices. It should be noted in this regard that the sales prices of caustic soda have been rising since the second quarter; this increase

16 Including the Organics cluster (SBU Molecular Solutions)
17 Including the Soda Ash and Derivatives SBU and Advanced Functional Minerals

should continue in the fourth quarter. Sales in the allylics activities were substantially higher than last year. The epichlorohydrin market improved significantly in 2010, especially thanks to a very strong demand for epoxy resins. This positive market context enabled Solvay to increase its sales volumes and its sales prices in this line of business. The operating result for the Electrochemistry cluster was significantly higher than last year.

- Sales and operating result for **Fluorinated Products** for nine months of 2010 improved significantly compared to last year thanks to high sales volumes in most products.

Oxygen cluster

- Sales volumes for hydrogen peroxide were maintained at a high level since the start of the year (+16% compared to the end of September 2009) thanks to strong overall demand for paper pulp (especially in Asia). Despite lower sales prices, the operating result at the end of September 2010 was clearly higher than last year.

PLASTICS SECTOR

Recent strategic developments

The Plastics Sector has taken advantage of the crisis to further increase its competitiveness in its various businesses while maintaining the emphasis on development of sustainable products and geographic expansion in high-growth markets.

Sustainable development, one of the major strategic priorities of the Group, recently materialized in the Sector through different projects and accomplishments. They illustrate the key of research and innovation in this area.

- A new range of SOLEF® designed for lithium-ion batteries was recently launched. It significantly increases the energy density (by 30 to 40%) of the batteries as well as their life span.
- A project of PVC production capacity extension by ethylene produced from bioethanol at Solvay Indupa in Brazil is under study.
- Many innovative Specialty Polymers find their application in the solar airplane Solar Impulse

Projects were also carried out in the energy field.

- In Argentina, a power plant of 120 MW, built in partnership with Albanesi on the Solvay Indupa site, has been in operation since the middle of 2009. Later, its capacity will be expanded to 165 MW.

Geographic expansion into high-growth countries constitutes one of the key strategic orientations of the Plastics Sector.

- In Vinyls, the project for construction of a new production unit in Russia of RusVinyl (joint venture between SolVin and Sibur), with an initial PVC capacity of 330,000 tons/year, is continuing. On July 12, 2010, the first stone of the plant was laid in the presence of Belgian Prime Minister Yves Leterme. Moreover, the Board of the EBRD approved to finance RusVinyl for EUR 150 million through a loan. Furthermore, the EBRD will contribute EUR 52 million to the equity of SolVin Holding Nederland BV (the entity holding SolVin's participation in RusVinyl). Startup of this plant is set for mid-2013.

  In Brazil, the recent modernization of the production unit significantly improved competitiveness at the Solvay Indupa site, among other things by production using membrane electrolysis and by an increase in PVC capacity to 300,000 tons/year.

  Southeast Asia, Mercosur and, in the future, Russia constitute significant areas of growth for vinyls.

- In Specialty Polymers, the Group is emphasizing expansion of its portfolio of high-performance polymers, especially in Asia. This region today represents about 30% of this SBU's sales. Thus in October 2010, Solvay announced the construction of a compounding plant for specialty polymers in China. This plant, which will first produce compounds for AMODEL®, IXEF® and KALIX®, will begin operations at the end of 2012.

The Sector also undertakes selective capacity expansions for production of some specialty polymers that are used in high value-added applications. Thus in September 2010, Solvay announced its decision to increase production capacity of TECNOFLON® (used mainly by the automotive industry and by the semi-conductor industry) at its site in Spinetta (Italy). In March 2009, a new production unit for DIOFAN® (used for coating of food products and pharmaceutical packaging), with annual capacity of 20,000 tons/year, started up on the Tavaux site (France). Other selective production capacity expansions realized in 2009 include SOLEF® at Tavaux (France) and FLUOROLINK® and PTFE micronized powder on the Spinetta site (Italy). These capacity expansions will support growth of FLUOROLINK® in the textile and paper coating market as well as SOLEF® in new applications such as photovoltaic cells, sensors and Lithium-ion batteries. Solvay today is fully benefiting from these increases in capacity in a context of strong demand for specialty polymers.

The recent economic crisis led the Plastics Sector to undertake a vast program of cost reduction and cash optimization. This translated into **different restructuring measures.** Some examples were the shutdown of the PVC compounds unit (BENVIC) at the Jemeppe site in Belgium, restructurings carried out throughout the whole

Specialty Polymers organization as well as the recent decision by Pipelife to shut down several production units (Croatia, Romania, Spain and Portugal).

Two new recent events should be recalled:

- The closing of the purchase by Plastic Omnium of Solvay's stake in Inergy Automotive Systems on September 8, 2010. Solvay received payment of EUR 268 million in cash for its shares and posted an after taxes capital gain of EUR 130 million.
- The decision by SolVin and Arkema to each purchase in the second half of 2010 the minority holding of the other in the joint ventures for vinyls production that they operate together. Vinilis (Spain) is now wholly owned by SolVin and no longer has a minority holding in the companies VinylFos and VinylBerre (France).

Key figures

(Million EUR)	Sales				REBIT change
	2009	9 months 2009	9 months 2010	9 months 10 / 9 months 09 (%)	9 months 10 / 9 months 09
PLASTICS	**2,982**	**2,180**	**2,923**	**34%**	↗
Specialties[18]	1,251	897	1,151	28%	↗
Vinyls[19]	1,731	1,283	1,772	38%	↗

Comments

- ***Operating result in the Plastics Sector clearly improved thanks to the strong recovery in demand for Specialty Polymers***
- ***In Vinyls, in the third quarter, SolVin was able to benefit from the slight recovery in demand in the context of a temporarily more limited supply***

Plastics Sector sales were clearly up compared to last year; at constant scope[20], they improved by 36% on a cumulative basis (EUR 2,923 million at the end of September 2010) and by 23% on a quarterly basis (EUR 918 million in the third quarter of 2010). This can be explained by the sharp increase in sales volumes in Specialty Polymers. Although all regions of the world were involved, this improvement was particularly notable in Asia. In Vinyls, improvement in sales was confirmed in the third quarter. SolVin was able to benefit from the slight recovery in demand in a context of supply that was temporarily more limited. Operating result from the Plastics Sector (EUR 261 million at the end of September 2010 and EUR 88 million in the third quarter of 2010) was clearly improved compared to last year (EUR 56 million at the end of September 2009 and EUR 42 million in the third quarter of 2009). This improvement was observed in both Vinyls and Specialty Polymers, although it was the latter that showed the highest growth in results.

Specialties

- Sales volumes of **Specialty Polymers** remained much sustained in the third quarter of 2010. On a cumulative basis, they improved by 42% compared to last year. This improvement can be seen across all activity sectors (fluorinated polymers, high-performance technical polymers, barrier polymers and performance compounds) and involves each region of the world. It is explained both by the recovery of the automotive and electronics sectors, heavily impacted last year by the global economic crisis, and by the strong growth in new applications such as alternative energies (photovoltaic, wind), lithium-ion batteries and high-performance membranes for water treatment. The operating result was clearly improved compared to the low level of last year. Aside from improvement in the amounts sold, the sector benefited from significant cost-reduction measures set up last year. The 3rd quarter was impacted by maintenance shutdowns at several plants. Research and development efforts, at the heart of the SBU's strategy, were maintained at the same level as in the past (on average 6% of sales).
- Only the results from the first 6 months of 2010 for **Inergy Automotive Systems** are included in the consolidated accounts for the Group at the end of September 2010 following purchase by Plastic Omnium of Solvay's stake in this company. It should be recalled that sales volumes for Inergy Automotive Systems for the first half of 2010 were significantly up (+46%) compared to the low level of the first half of 2009, which explains the record level of the operating result for the first half of 2010 of this business.

Vinyls

- In Europe, a slight increase in demand for PVC has been observed since the month of March even though the construction sector remains depressed in some European countries. SolVin benefited from this slight recovery in demand in the context of a temporarily more limited supply. Against this background, the sales prices went up in the third quarter of 2010 while the cost of ethylene remained globally stable. The operating result for SolVin was clearly improved from last year. In Mercosur, PVC demand has remained at a good level since the start of the year. The increase in sales, however, was not reflected in the operating result of Solvay Indupa;

18 Including the Specialty Polymers SBUs and Inergy Automotive Systems (until June 30, 2010)
19 Including the Vinyls SBUs and Pipelife
20 The primary variations in the perimeter between nine months 2009 and nine months 2010 are shown on page 15 of this press release.

production problems linked to supply problems with ethylene and other utilities as well as unfavorable macroeconomic factors (inflation, strength of the Brazilian Real and Argentine Peso) weighed significantly. In Asia, the situation remained positive both for sales volumes and for profit margin.

- Sales volumes and results from **Pipelife** were down compared to last year. They were affected by the weak European construction sector and by the impact of public deficit reduction in infrastructure works and civil engineering. Additional restructuring and cost reduction measures are under way, such as the announced closures of production units in Spain, Portugal, Croatia and Romania.

NEW BUSINESS DEVELOPMENT (NBD)

In order to better demonstrate the research activities undertaken, outside the Strategic Business Units, in promising and important areas for development of the Group, it was decided to introduce in the financial reporting, starting in 2010, a specific segment for the New Business Development (NBD).

Recent strategic developments

The NBD segment of activities aims to create innovative materials and systems using leading edge technologies, beyond those being implemented today in the Strategic Business Units, in promising and important areas for development of the Group.

The NBD activity is organized into **strategic platforms** that combine programs linked to a common theme.

- The **Printable Organic Electronics platform** aims at development of "inks" that should enable mass, low-cost and energy-efficient production of different goods such as panel displays and lighting using organic electroluminescent diode (OLED), as well as organic semi-conductors.
- The **Renewable Energies platform** concentrates its work on fuel cells and organic photovoltaic cells.
- The **Nanotechnology platform** manages different projects in this area that are directly linked to Group activities.
- The purpose of the **Renewable Chemistry platform** is to explore the potential development of Solvay in this area; it is proceeding with a systematic cartography of renewable materials likely to be used by the chemical industry. It supports several projects for operating units in the Group.

In 2010, the **budgeted NBD expenses for the future** amounted to EUR 55 million (research and development expenses of about EUR 30 million and investments of about EUR 25 million).

The **research and development activities** are implemented both internally and externally ("open innovation"). Thus:

- A team of about 20 scientists, based in Neder-over-Heembeek (Belgium), does research on organic electronics. In this regard, it should be noted that recent tests demonstrated a life span greatly superior to 100,000 hours for OLED structures incorporating original materials developed and patented by Solvay.
- Numerous research partnerships were concluded, such as, for example, the Solvay Global Discovery Program (an international research consortium that involves prestigious universities including Georgia Tech, Princeton University, the University of Washington, Imperial College London and the Chinese Academy of Sciences) in the area of organic semi-conductors.
- NBD and the Specialty Polymers SBU continue to work on Proton Exchange Membrane (PEM) fuel cells whose efficiency can be increased by using Aquivion™ PFSA (perfluorosulfonic acid polymers).
- Solvay is participating with a partner in a project aiming to produce bio-sourced polymers with the use of industrial biotechnologies in the framework of the BioHub® research program.

Solvay makes **investments** in venture capital funds (Conduit Ventures Limited, Pangaea Ventures Fund II, Korea Advanced Materials Fund and Capricorn Cleantech Fund) and in start-ups (Plextronics, Inc., Polyera Corporation, ACAL Energy Ltd and Amminex A/S) active in areas similar to those in the NBD strategic platforms. To date, Solvay has committed to invest about EUR 60 million (of which about one third still remained to be cashed out) in these different funds and startups, including USD 22 million in Plextronics, Inc., specializing in development and marketing of polymer-based technologies for printable electronics, such as OLED lighting and screens and organic photovoltaic cells.

Additionally, Solvay has a holding of 50% in **SolviCore**, a joint venture developed with Umicore. This enterprise produces membrane-electrode assemblies that constitute the heart of the fuel cell.

The NBD team continues to evaluate new investment opportunities with respect to the four platforms currently selected.

The following **recent accomplishments** in this segment of activities should be noted:

- Solvay committed to paying EUR 13 million to the Korean venture capital fund, Korea Advanced Materials Fund, that will invest in promising technologies in the areas of renewable energy, printed electronics, clean technologies and green chemistry.
- In September 2010, Solvay invested USD 4 million for a minority holding in Polyera Corporation, a leader in the development of materials for the printable electronics market based in the United States.

- In February 2010, Solvay announced a project for construction of one of the largest fuel cells in the world at the SolVin site at Antwerp (Belgium). With this facility with a capacity of on average 1 MW, Solvay intends to demonstrate the strength of its innovative specialty polymers when they are subjected to extreme conditions at the heart of the fuel cell with proton-exchanging membranes.
- In March 2010, Solvay decided to participate in an increase in the capital of ACAL Energy Ltd, designed to finance development and commercialization of stationary fuel cells using the FlowCath® technology invented by this company.
- In August 2009, Solvay announced the increase in its holdings in Plextronics, Inc. Solvay currently holds 29% of the issued capital of this company.

REMARKS

1. Consolidated financial statements.

Deloitte conducted a limited review of the consolidated situation closed on September 30, 2010. This review consisted primarily of analysis, comparison and discussion of financial information and was thus less extensive than a review designed for a full audit of the annual books. This review revealed no items that would imply significant corrections to the intermediate situation.
The consolidated financial statements were prepared in conformity with IFRS standards as currently adopted in the European Union. These standards did not have any impact on the consolidated financial statements, either for the current period or the comparison period. The primary variations in perimeter between nine months of 2009 and 2010 involve:

- The sale of the pharmaceuticals activities on February 15, 2010.
- Consolidation at 100% of Vinythai as of December 31, 2009 with minority interests of 50%, following crossing of the 50% threshold that ensures control of the enterprise (results from Vinythai remained consolidated at 50% for the entire period of 2009).
- As of January 1, 2010, consolidation at 100% of Solvay Specialty Polymers (Changshu) Co. Ltd and equity accounting for Solalban Energia (Argentina).
- The reintroduction in the Chemicals segment of the assets and liabilities linked to the precipitated calcium carbonate activity, following the decision to terminate the sale process for this activity.
- The sale of Inergy Automotive Systems effective July 1, 2010.

2. Information on impairments of industrial assets (IAS 36.9)

- An impairment of industrial assets, belonging to the "cash-generating unit" covering the activities of soda ash in Europe and Egypt and calcium chloride, amounting to EUR 244 million (after-tax impact of EUR 186 million) was recorded in the third quarter of 2010. The assets concerned are primarily tangible assets. Soda ash in Europe is confronted with the persistent weakness of some of its markets, including flat glass used in construction.
- An impairment of industrial assets, belonging to the “cash-generating unit” covering the activities of the electrochemistry site at Bussi, Italy, amounting to EUR 14 million (after tax impact of EUR 10 million) was recorded in the third quarter of 2010. The projected cash flow generation from activities still present on this site no longer justifies the residual value. The assets concerned are primarily tangible assets.

3. Content.

This press release contains regulated information and is established in compliance with the IAS 34 standard. A risk analysis is shown in the annual report, which is available on the Internet (www.solvay-investors.com).

4. Primary exchange rates.

		Closing			Average		
1 Euro =		2009	9 months 2009	9 months 2010	2009	9 months 2009	9 months 2010
Pound Sterling	GBP	0.8881	0.9093	0.8599	0.8910	0.8863	0.8573
American Dollar	USD	1.4406	1.4643	1.3648	1.3948	1.3662	1.3148
Argentine Peso	ARS	5.4839	5.6442	5.4152	5.1983	5.0718	5.1253
Brazilian Real	BRL	2.5113	2.6050	2.3201	2.7671	2.8345	2.3416
Thai Baht	THB	47.986	48.988	41.442	47.806	47.320	42.466
Japanese Yen	JPY	133.16	131.07	113.68	130.33	129.53	117.66

5. Solvay shares.

	2009	9 months 2009	9 months 2010
Number of shares issued at the end of the period	84,701,133	84,701,133	84,701,133
Average number of shares for IFRS calculation of earnings per share	82,143,247	82,136,569	81,431,355
Average number of shares for IFRS calculation of diluted income per share	82,186,334	82,155,163	81,592,533

6. Declaration by responsible persons.

Mr. C. Jourquin, Chairman of the Executive Committee, and Mr. B. de Laguiche, Chief Financial Officer, declare that to the best of their knowledge:

a) the summary financial information, prepared in conformity with applicable accounting standards, reflects a faithful image of the net worth, financial situation and results of the Solvay Group;
b) the intermediate report contains a faithful presentation of significant events occurring during the first nine months of 2010, and their impact on the summary financial situation;
c) there are no transactions with affiliated parties.

Key dates for financial communications

- January 13, 2011: Prepayment on dividend for 2010
- February 17, 2011: Annual results for 2010 (7:30 AM)

To obtain additional information:

Erik De Leye
*Corporate Press Officer (*SOLVAY S.A.)
Tel: 32 2 509 72 30
E-mail : erik.deleye@solvay.com
Internet: www.solvaypress.com

Patrick VERELST
Head of Investor Relations (SOLVAY S.A.)
Tel: 32 2 509 72 43
E-mail : patrick.verelst@solvay.com
Internet: www.solvay-investors.com

Solvay Investor Relations, SOLVAY S.A., Tel. 32-2-509.60.16, E-mail : investor.relations@solvay.com

SOLVAY is an international industrial Group active in Chemistry. It offers a broad range of products and solutions that contribute to improving quality of life. The Group is headquartered in Brussels and employs about 17,000 people in 40 countries. In 2009, its consolidated sales amounted to EUR 8.5 billion. Solvay is listed on the NYSE Euronext stock exchange in Brussels (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR). Details are available at www.solvay.com.

Dit persbericht is ook in het Nederlands beschikbaar – Ce communiqué de presse est aussi disponible en français